Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Possible noradrenergic dysfunction in schizophrenia

K Yamamoto1, N Ozawa, T Shinba

  • 1Department of Neurophysiology, Tokyo Institute of Psychiatry, Japan.

Brain Research Bulletin
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone marrow stromal cells attenuate mitoxantrone cytotoxicity against HL-60 leukemic cells.

Anti-cancer drugs·1992
Same author

[The resolution of D- and L-amino acids by reversed-phase high-performance liquid chromatography].

Seikagaku. The Journal of Japanese Biochemical Society·1992
Same author

[Antimutagenic substances in the Armeniacae semen and Persicae semen].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·1992
Same author

Two sudden death cases of idiopathic ventricular tachycardia.

The Tokushima journal of experimental medicine·1992
Same author

A case of concealed WPW syndrome with three different reciprocal tachycardias due to triple AV nodal pathways.

The Tokushima journal of experimental medicine·1992
Same author

Effects of phosphate in the production of hemolysin in Vibrio parahaemolyticus.

East African medical journal·1992

Schizophrenia research suggests noradrenergic dysfunction, not dopamine, may explain symptoms. Animal models show noradrenergic activity can reproduce and treat schizophrenia-like behaviors, offering new therapeutic insights.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Dopamine hypothesis of schizophrenia lacks undisputed experimental support.
  • Consistent results emerge from studying noradrenaline (a key catecholamine) and its metabolites.
  • Noradrenergic dysfunction is increasingly implicated in schizophrenia pathogenesis.

Purpose of the Study:

  • To investigate the role of noradrenergic dysfunction in schizophrenia using animal models.
  • To determine if schizophrenic signs and symptoms can be reproduced by altering noradrenergic activity.
  • To assess the treatability of schizophrenia-like behaviors through modulation of noradrenergic pathways.

Main Methods:

  • Animal experiments were conducted to model schizophrenia.
  • Psychophysiological signs like skin conductance responsiveness and smooth pursuit eye movements were monitored.

Related Experiment Videos

  • The effects of drugs, including haloperidol, on noradrenergic activity and behavioral symptoms were analyzed.

    • Main Results:

    • Enhancing or suppressing central noradrenergic activity reproduced specific psychophysiological signs associated with schizophrenia.
    • Behavioral abnormalities resembling schizophrenic symptoms were linked to noradrenergic over- or underactivity (overarousal or underarousal syndromes).
    • Chronic haloperidol administration demonstrated a potent suppressing effect on skin conductance activity, indicating inhibition of noradrenergic activity.

    Conclusions:

    • Noradrenergic dysfunction plays a significant role in the pathogenesis of schizophrenia.
    • Animal models successfully replicated and responded to modulation of noradrenergic activity, supporting its therapeutic potential.
    • Findings suggest that targeting the noradrenergic system may offer novel treatment strategies for schizophrenia.